...
首页> 外文期刊>Biotechnology & Biotechnological Equipment >Clinical assessment of the therapeutic effect of low-level laser therapy on chronic recurrent aphthous stomatitis
【24h】

Clinical assessment of the therapeutic effect of low-level laser therapy on chronic recurrent aphthous stomatitis

机译:低水平激光治疗慢性复发性口疮性口炎的疗效评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to clinically assess the therapeutic effect of low-level laser therapy (LLLT) on chronic recurrent aphthous stomatitis (RAS) using a protocol we developed especially for the purpose. The study included 180 patients: group 1 (the study group) ?¢???? 90 patients who received LLLT using a laser operating in the red spectrum (658????nm; in a non-contact mode; power output P = 27 mW; frequency f 1 = 5.8????Hz, f 2 ?¢???? continuous waveform; time T = 1.14????min; dosage of 2 J/cm 2 once daily); group 2 (controls) ?¢???? 90 patients who received pharmacotherapy (Granofurin and solcoseryl given twice daily). The indices we assessed were pain intensity, erythema dynamics and epithelization time. Pain was completely managed in 55.6% of group 1 patients one day after therapy began, while it took three days to alleviate pain for 11.1% of the patients in group 2. The erythema was managed entirely in 24.4% of group 1 patients after the first session, while it did not change in any of the group 2 patients. Pain intensity and erythema had similar dynamics for both groups. In 5????days, 75.6% of group 1 patients showed complete epithelization, while in group 2 the process was completed in only 37.8% of patients. As a whole, the results we obtained using LLLT to treat chronic RAS were better than those obtained in the group receiving pharmacotherapy. Pain and inflammation were very effectively managed with LLLT with the parameters we used and epithelization was considerably accelerated.
机译:这项研究的目的是使用我们专门为此目的开发的协议,对低水平激光疗法(LLLT)对慢性复发性口疮性口炎(RAS)的治疗效果进行临床评估。该研究包括180位患者:第1组(研究组) 90位使用红色光谱(658?nm;非接触模式)的激光接受LLLT的患者;功率输出P = 27 mW;频率f 1 = 5.8?Hz,f 2?连续波形;时间T = 1.14分钟;每天2J / cm 2剂量。第2组(控件) 90例接受药物治疗的患者(每天两次给予格拉夫林和索可塞灵)。我们评估的指标是疼痛强度,红斑动态和上皮形成时间。在开始治疗的第一天,完全治愈了15.6%的第一组患者的疼痛,而在第二组的11.1%的患者中花了三天的时间来缓解疼痛。第一次治疗后,第一组的24.4%的患者完全缓解了红斑。疗程中,第2组的任何患者均无变化。两组的疼痛强度和红斑动态相似。在第5天,第1组患者的75.6%表现出完全的上皮形成,而在第2组中,只有37.8%的患者完成了该过程。总体而言,我们使用LLLT治疗慢性RAS的结果要好于接受药物治疗的组。使用我们所使用的参数,使用LLLT非常有效地控制了疼痛和炎症,并且明显加快了上皮形成的速度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号